[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353560-105":59,"doc-detail-353560-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","chemotherapy-improves-survival-for-patients-with-lymph-node-negative-invasive-papillary-breast-cancer-with-tumors-2-cm-a-seer-population-based-study","Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm - a SEER population-based study","","Background: Invasive papillary breast cancer (IPC) is rare and has a generally better prognosis than other breast cancers. This study examined whether early-stage IPC patients benefit from chemotherapy. Materials and Methods: IPC cases diagnosed from 2003 to 2021 were extracted from the SEER database; Kaplan–Meier and Cox models assessed prognostic factors and propensity score matching reduced selection bias. Results: Chemotherapy improved overall survival for lymph node-negative IPC with tumors ≥2.0 cm and for grade III/undifferentiated disease. Conclusions: Chemotherapy should be considered in these subgroups to reduce undertreatment, and randomized trials are warranted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chemotherapy-improves-survival-for-patients-with-lymph-node-negative-invasive-papillary-breast-cancer-with-tumors-2-cm-a-seer-population-based-study/353560/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chemotherapy-improves-survival-for-patients-with-lymph-node-negative-invasive-papillary-breast-cancer-with-tumors-2-cm-a-seer-population-based-study/353560.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the study on invasive papillary breast cancer?","Question",{"text":112,"@type":113},"The study aimed to determine whether patients with early-stage invasive papillary breast cancer could benefit from chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and how was bias addressed?",{"text":117,"@type":113},"Cases diagnosed between 2003 and 2021 were retrieved from the SEER database, and propensity score matching (PSM) was used to reduce selection bias and adjust baseline characteristics.",{"name":119,"@type":110,"acceptedAnswer":120},"Which patients showed improved outcomes with chemotherapy?",{"text":121,"@type":113},"Chemotherapy significantly improved overall survival for lymph node-negative IPC patients with tumors ≥2.0 cm, and for patients with grade III or undifferentiated disease.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353560,1790156551,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study  \nYizi Zheng, PhD1,2, *,, Zhuozhao Zhan, PhD3,, Tingting Wu, MD1, Jiaqi Ying, MD1, Aina Zheng, MD4  \n1Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China  \n2Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen University, Shenzhen, Guangdong 518035, China  \n3Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, AZ 5612, The Netherlands 4The Operating Theater, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China  \n\\#Corresponding author: Yizi Zheng, Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China ([zhengyizi@wmu.edu.cn](zhengyizi@wmu.edu.cn)) .  \nAbstract  \nBackground: Invasive papillary breast cancer (IPC) is a rare cancer known to have a better prognosis than other breast cancers. This study aimed to explore whether patients with early-stage IPC can benefit from chemotherapy.  \nMaterials and Methods: IPC cases diagnosed between 2003 and 2021 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan–Meier method and the Cox proportional hazard model were performed to identify significant prognostic factors. To eliminate selection bias and baseline characteristics, propensity score matching (PSM) was used. The primary endpoints were overall survival (OS) and breast cancer-specific survival (BCSS) .  \nResults: A total of 1892 patients were enrolled, and 273 pairs were screened after PSM. Multivariable analysis showed that age under 50, married status, smaller tumor size, negative lymph node (LN) status, and receipt of surgery, chemotherapy or radiotherapy were independently associated with better OS. After PSM, patients receiving chemotherapy had significantly improved OS (P = .012), while BCSS showed no significant difference ( P = .099) . After stratified by tumor size and LN status, chemotherapy could significantly improve the OS of patients with LN-negative IPC with tumors ≥ 2.0 cm ( P\u003C .001) . Among the patients with grade III or undifferentiated diseases, the OS of the chemotherapy group was significantly better than that of the non-chemotherapy group ( P\u003C .001) .  \nConclusions: For patients with LN-negative IPC with tumor ≥ 2.0 cm and patients with grade III or undifferentiated disease, chemotherapy significantly improved OS. Future randomized controlled trials are expected to validate the results.  \nKey words: breast cancer; invasive papillary carcinoma; chemotherapy; prognosis.  \nImplications for Practice  \nConducting prospective studies on IPC to assess the efficacy of chemotherapy remains challenging due to its rarity. Leveraging a large population-based dataset, our study demonstrated that chemotherapy significantly improved overall survival in patients with lymph node-negative IPC with tumors ≥ 2 cm, as well as those with grade III or undifferentiated disease. Chemotherapy should be considered in these populations to avoid undertreatment.  \nIntroduction  \nInvasive papillary carcinoma (IPC) of the breast represents a rare pathological subtype of breast cancer. According to the World Health Organization’s (WHO) classification of breast tumors, as delineated in the fifth edition published in 2019, IPC is characterized as “invasive adenocarcinoma with papillary structure constituting greater than 90% of the invasive components.”1 This subtype accounts for approximately 0.5% to 2% of all invasive breast cancers.2–4  \nPrevious studies have found that IPC has higher","cbCaioipx0cOZz4n","https://ap.wps.com/l/cbCaioipx0cOZz4n","pdf",2512422,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusions\n# Implications for Practice\n# Introduction","[{\"question\":\"What was the purpose of the study on invasive papillary breast cancer?\",\"answer\":\"The study aimed to determine whether patients with early-stage invasive papillary breast cancer could benefit from chemotherapy.\"},{\"question\":\"How were patients selected and how was bias addressed?\",\"answer\":\"Cases diagnosed between 2003 and 2021 were retrieved from the SEER database, and propensity score matching (PSM) was used to reduce selection bias and adjust baseline characteristics.\"},{\"question\":\"Which patients showed improved outcomes with chemotherapy?\",\"answer\":\"Chemotherapy significantly improved overall survival for lymph node-negative IPC patients with tumors ≥2.0 cm, and for patients with grade III or undifferentiated disease.\"}]","Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm - a SEER population-based study | PDF",1790106041,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bde4d2b679a3a3597fa08c1c3a839489.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b87d33c75157c693ee064903327a8162.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0834a96d4cb6bfa2cc2581acd3aeb090.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e246fb2d221565ceabc2d75f81ebf1cb.webp",980,1287]